CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia
CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia
复制标题
严重再生障碍性贫血患者对利妥昔单抗耐药的 CD20 阴性 Epstein-Barr 病毒相关移植后淋巴增殖性疾病
DOI：
10.1007/s12185-011-0870-3
复制
发表时间：
2011
期刊：
影响因子：
2.1
通讯作者：
Ito M and Kojima S.
中科院分区：
文献类型：
--
作者：
Mur amatsu H;Takahashi Y;Shimoyama Y;Doisaki S;Nishio N;Ito Y;Hama A;Shimada A;Yagasaki H;Ito M and Kojima S.
EB病毒相关性移植后淋巴增生性疾病(EBV-PTLD)是异基因造血干细胞移植(HSCT)后的一种危及生命的并发症。监测高危患者的EBV DNA是非常有效的，可以预防HSCT后的EBV相关疾病。在这里，我们报告了一个10岁的再生障碍性贫血女孩，她在非亲缘骨髓移植后发展为CD20阴性的EBV-PTLD，对利妥昔单抗治疗无效。与其他类型的淋巴瘤相似，CD20抗原的缺失可能是利妥昔单抗耐药的EBV-PTLD的特征。
Epstein–Barr virus-associated post-transplant lymphoproliferative disease (EBV-PTLD) is a life-threatening complication following allogeneic hematopoietic stem cell transplantation (HSCT). Monitoring of EBV DNA in high-risk patients with subsequent pre-emptive rituximab treatment is highly effective, and can prevent EBV-associated disease following HSCT. Here, we report a 10-year-old girl with aplastic anemia who developed CD20 negative EBV-PTLD after unrelated bone marrow transplantation that was refractory to rituximab treatment. Similar to other types of lymphoma, the absence of CD20 antigen is likely to be characteristic of rituximab-refractory EBV-PTLD.